deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)

versus placebo
pembrolizumab alone vs. placebo 1 certainty unassessable-42%- certainty unassessablestatistically conclusive-29%